Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

2010 Cancer Cell 1,218 citations

Abstract

BRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhibitors is a significant clinical challenge. We describe a model of resistance to BRAF inhibitors developed by chronic treatment of BRAF(V)⁶⁰⁰(E) melanoma cells with the BRAF inhibitor SB-590885; these cells are cross-resistant to other BRAF-selective inhibitors. Resistance involves flexible switching among the three RAF isoforms, underscoring the ability of melanoma cells to adapt to pharmacological challenges. IGF-1R/PI3K signaling was enhanced in resistant melanomas, and combined treatment with IGF-1R/PI3K and MEK inhibitors induced death of BRAF inhibitor-resistant cells. Increased IGF-1R and pAKT levels in a post-relapse human tumor sample are consistent with a role for IGF-1R/PI3K-dependent survival in the development of resistance to BRAF inhibitors.

Keywords

PI3K/AKT/mTOR pathwayKinaseMelanomaCancer researchMEK inhibitorMAPK/ERK pathwayBiologyChemistrySignal transductionCell biology

MeSH Terms

Cell LineTumorDrug ResistanceNeoplasmHumansMAP Kinase Signaling SystemMelanomaMitogen-Activated Protein Kinase KinasesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphorylationProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-aktReceptorIGF Type 1raf Kinases

Affiliated Institutions

Related Publications

Publication Info

Year
2010
Type
article
Volume
18
Issue
6
Pages
683-695
Citations
1218
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1218
OpenAlex
59
Influential
1061
CrossRef

Cite This

Jessie Villanueva, Adina Vultur, John Tayu Lee et al. (2010). Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. Cancer Cell , 18 (6) , 683-695. https://doi.org/10.1016/j.ccr.2010.11.023

Identifiers

DOI
10.1016/j.ccr.2010.11.023
PMID
21156289
PMCID
PMC3026446

Data Quality

Data completeness: 90%